Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis. (PubMed, Expert Opin Biol Ther) - Aug 30, 2026 - "SHAP identified prior immunotherapy (pembrolizumab, atezolizumab/nivolumab), radiotherapy, and upper tract tumors with lower mortality risk; lung, liver, bone, soft tissue metastases increased risk. XGBoost and Elastic Net offer modest risk stratification, that are hypothesis generating but does not support routine clinical use. Functional status, metastatic pattern, and treatment context are key drivers, providing a foundation for externally validated prognostic tools."
Journal • Real-world evidence • Oncology • Solid Tumor • Urothelial Cancer
|
|
Alfonso Gómez de Liaño; Alina Pirshtuk; Augusto Mota; Francesco Massari; Gowri Sivaramakrishnan; Jakub Kucharz; Javier Molina Cerrillo; Joaquim Bellmunt; Kannan Sridharan; Marc R Matrana; Martin Angel; Matteo Santoni; Ondrej Fiala; Patrizia Giannatempo; Ravindran Kanesvaran; Shilpa Gupta; Thomas Büttner; Tomas Soule; Yüksel Ürün; Zin W Myint
|